ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Hot Features

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
Entrar Premium IconPremium Help Menu
Índice Bovespa
127.411,55
-0,27%
S&P 500
5.321,41
0,25%
US Dollar vs BRL
5,1189
0,28%
Bitcoin
69.689,76
-2,46%
Brent Oil
82,445
-1,30%
Registration Strip Icon for smarter Negocie de forma mais inteligente, não mais difícil: Libere seu potencial com nosso conjunto de ferramentas e discussões ao vivo.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. Gemini Therapeutics Inc (GMTX)

  7. Gemini Therapeutics Inc (GMTX) Notícias

GMTX

Gemini Therapeutics (GMTX)

Gemini Therapeutics Inc
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:GMTX
DataHoraFonteTítuloCódigoCompanhia
29/06/202317:18Edgar (US Regulatory)Report of Proposed Sale of Securities (144)NASDAQ:GMTXGemini Therapeutics Inc
28/06/202318:23Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:GMTXGemini Therapeutics Inc
21/06/202317:54Edgar (US Regulatory)Amended Statement of Beneficial Ownership (sc 13d/a)NASDAQ:GMTXGemini Therapeutics Inc
20/06/202317:02Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:GMTXGemini Therapeutics Inc
16/06/202308:16Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:GMTXGemini Therapeutics Inc
15/06/202307:26Edgar (US Regulatory)Prospectus Filed Pursuant to Rule 424(b)(5) (424b5)NASDAQ:GMTXGemini Therapeutics Inc
15/05/202308:17Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:GMTXGemini Therapeutics Inc
20/04/202308:06Edgar (US Regulatory)Additional Proxy Soliciting Materials (definitive) (defa14a)NASDAQ:GMTXGemini Therapeutics Inc
20/04/202308:03Edgar (US Regulatory)Proxy Statement (definitive) (def 14a)NASDAQ:GMTXGemini Therapeutics Inc
31/03/202308:20Edgar (US Regulatory)Annual Report (10-k)NASDAQ:GMTXGemini Therapeutics Inc
24/02/202318:48Edgar (US Regulatory)Statement of Ownership (sc 13g)NASDAQ:GMTXGemini Therapeutics Inc
25/01/202308:03Edgar (US Regulatory)Notice of Effectiveness (effect)NASDAQ:GMTXGemini Therapeutics Inc
18/01/202308:02Edgar (US Regulatory)Securities Registration: Employee Benefit Plan (s-8)NASDAQ:GMTXGemini Therapeutics Inc
18/01/202308:02Edgar (US Regulatory)Securities Registration Statement (simplified Form) (s-3)NASDAQ:GMTXGemini Therapeutics Inc
09/01/202318:05Edgar (US Regulatory)Initial Statement of Beneficial Ownership (3)NASDAQ:GMTXGemini Therapeutics Inc
09/01/202318:03Edgar (US Regulatory)Statement of Beneficial Ownership (sc 13d)NASDAQ:GMTXGemini Therapeutics Inc
27/12/202210:56Dow Jones NewsGemini Therapeutics Shares Rise After Disc Medicine Gets FDA DesignationNASDAQ:GMTXGemini Therapeutics Inc
27/12/202210:08Edgar (US Regulatory)Filing of Certain Prospectuses and Communications in Connection With Business Combination Transactions (425)NASDAQ:GMTXGemini Therapeutics Inc
27/12/202210:00PR Newswire (US)Disc Medicine Receives FDA Orphan Drug Designation for Bitopertin for the Treatment of Erythropoietic ProtoporphyriaNASDAQ:GMTXGemini Therapeutics Inc
31/10/202210:00PR Newswire (US)Disc Medicine Initiates AURORA, a Phase 2 Clinical Study of Bitopertin in Adults with Erythropoietic Protoporphyria (EPP)NASDAQ:GMTXGemini Therapeutics Inc
02/09/202218:11Edgar (US Regulatory)Securities Registration: Business Combination (s-4)NASDAQ:GMTXGemini Therapeutics Inc
10/08/202208:30Business WireGemini Therapeutics and Disc Medicine Announce Merger AgreementNASDAQ:GMTXGemini Therapeutics Inc
22/07/202206:39TipRanksGemini Therapeutics (GMTX) Gets a Hold Rating from SVB SecuritiesNASDAQ:GMTXGemini Therapeutics Inc
11/03/202208:08Edgar (US Regulatory)Post-effective Amendment to Registration Statement (pos Am)NASDAQ:GMTXGemini Therapeutics Inc
10/03/202209:00Business WireGemini Therapeutics Reports 2021 Financial ResultsNASDAQ:GMTXGemini Therapeutics Inc
09/03/202220:16Edgar (US Regulatory)Amended Statement of Changes in Beneficial Ownership (4/a)NASDAQ:GMTXGemini Therapeutics Inc
28/02/202210:37Edgar (US Regulatory)Prospectus Filed Pursuant to Rule 424(b)(3) (424b3)NASDAQ:GMTXGemini Therapeutics Inc
28/02/202210:30Business WireGemini Therapeutics Provides Corporate UpdateNASDAQ:GMTXGemini Therapeutics Inc
04/02/202210:02Edgar (US Regulatory)Schedule 13gNASDAQ:GMTXGemini Therapeutics Inc
10/01/202210:00Business WireGemini Therapeutics Provides GEM103 Program UpdateNASDAQ:GMTXGemini Therapeutics Inc
 Apresentando as notícias mais relevantes sobre:NASDAQ:GMTX

Seu Histórico Recente

USOTC
KAOCF
Kao (PK)
Delayed Upgrade Clock
ADVFN Logo

Brasil
Empresa
Negócios
Popular
Obter o aplicativo

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados